Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Player Avatar foolphighter (< 20) Submitted: 1/12/2007 2:11:42 AM : Outperform Start Price: $6.02 DVAX Score: -117.04

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its TOLAMBA allergy drug failed to show therapeutic benefit based on interim analysis, that appears to present a buying opportunity, particularly since the reason for the failure appears to be the lack of clinically significant disease in the study population. Cash of $1.50/share & no debt and the recent filing of a $100M shelf registration suggests the company is well-positioned to leverage its recent progress into further positive developments. the stock appears to offer a reasonable risk/reward after the recent sell-off.

Featured Broker Partners